Engineered Nanomaterials for Diagnosis, Prevention and Therapy

Dear Colleagues,

Biologically active engineered nanomaterials are indispensable tools in healthcare research, bringing innovative approaches to diagnosis, treatment, and disease management, and offering a transformative outlook. Their precise and targeted therapeutic capabilities hold promise for mitigating several unmet diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases, not to mention chronic hepatic and renal disorders. Biologically active nanomaterials can be engineered to deliver drugs, genes, or therapeutic agents with precision to specific cells or tissues, minimizing off-target effects and enhancing treatment efficacy. Notably, several of these nanomaterials can traverse biological barriers, such as the blood–brain barrier, enabling the treatment of previously inaccessible diseases and conditions. In addition, engineered nanomaterials can significantly contribute to diagnostics by enabling the development of highly sensitive and specific nano-based biosensors, imaging agents, and diagnostic tools. Therefore, in the face of an aging global population and the growing complexity of diseases, the potential of engineered nanomaterials to enhance drug delivery, diagnostics, and personalized medicine positions this topic as a pivotal field for advancing healthcare solutions. This Special Issue of Biomedicine is focused on the recent advances, methods, and approaches in preparing engineered nanomaterials and their applications in the diagnosis, prevention and therapy of diseases.

This Special Issue seeks to gather high-quality original research contributions, reviews, and perspectives from experts in the field, fostering collaboration and knowledge exchange among researchers, clinicians, and policymakers interested in the innovative use of nanomaterials to improve healthcare outcomes.

Suitable topics include, but are not limited to, the following:

• Engineered nanomaterials for cancer therapy;
• Engineered nanomaterials platform for viral infections;
• Nanomedicine strategies for vaccine delivery;
• Engineered nanomaterials for immune engineering;
• Nanomedicine: Pharmacokinetics, Pharmacodynamics and Toxicity;
• Engineered nanomaterials for topical and transdermal delivery;
• Engineered nanomaterials for oral delivery;
• Engineered nanomaterials for parenteral delivery;
• Engineered nanomaterials as redox medicine;
• Nanomedicine for ocular diseases;
• Nanomedicine for diabetes and its complications;
• Nanomedicine for inflammatory diseases;
• Nanotherapeutic approaches targeting mitochondria;
• Biosensors for disease diagnosis;
• Implantable biosensors;
• Nanotheranostic materials;
• Engineered nanomaterials for wound healing.

Dr. Aniruddha Adhikari
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.